Polychromatic Light Exposure as a Therapeutic in the Treatment and Management of Parkinson's Disease: A Controlled Exploratory Trial.

Front Neurol · 2018 · PMC6156259 · PMID 30778331

Europe PMC DOI

hedged sentences

0.0130

closest p · 0.3× alpha

0.0840

boldest claim

The sentences

highly significantp = 0.013actually significant

As shown in Figure 2A there was an improvement in the total PDQ39 score for the patients continued on polychromatic light and this was highly significant (SFAR, p = 0.013).

also in 132,142 other papers

a strong trendp = 0.065so close (0.05 < p ≤ 0.1)

Withdrawing light from patients, however, produced a strong trend of improvement (SFAR, Median for PRE = 1.0; W1 = 1.0; W2 = 0.0: Q1 for PRE = 0.5; W1 = 0.0; W2 = 0.0: Q3 for PRE = 5.5; W1 = 2.0; W2 = 1.5, p = 0.065).

also in 5,725 other papers

a weak trendp = 0.084so close (0.05 < p ≤ 0.1)

In part IV of the MDSUPDRS there was a trend revealed for the main effect in the RLG (SFAR, 0.223; p = 0.095), with further examination revealing a weak trend between PRE and W1 (RSWSRT, p = 0.084).

also in 1,404 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.